RxDoctor Payments Data

Scott Schwendiman, MD

Family Medicine · Boise, IDNPI 1538110234

Payments from drug & device makers

$1,672in general payments, 2019–2025

Across 85 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$396
  • Pfizer$201
  • Novo Nordisk$184
  • Lilly USA, LLC$117
  • Amgen$94
  • Stryker$79
  • plus $599 from 26 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,60796%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,672 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$32,002
Medicare patients
78
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$38,626
EliquisApixaban45$33,876
Tresiba Flextouch U-200Insulin Degludec20$18,131
FarxigaDapagliflozin Propanediol15$12,247
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,771
Breo ElliptaFluticasone/Vilanterol11$6,682
Carbamazepine ErCarbamazepine22$2,485
Levothyroxine Sodium188$1,952
Estradiol16$1,680
Omeprazole102$1,626
Bupropion XlBupropion Hcl24$1,227
Albuterol Sulfate HfaAlbuterol Sulfate39$944
Atorvastatin Calcium99$849
Tamsulosin Hcl48$705
Rosuvastatin Calcium65$685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$184$38,62627 claims
PfizerEliquis$201$33,87645 claims
GSKAnoro Ellipta, Breo Ellipta$30$13,45324 claims
AstraZenecaFarxiga$396$12,24715 claims
Lilly USA, LLCOlanzapine$117$16314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.

Other family medicine in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →